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number of patients for whom the scan was appropriate or not
in terms of the diagnostic algorithm. It can be seen that the
number of scans could have been reduced to 6. Two of the 16
negative scans could have been avoided if a policy was in force
of only scanning patients with anaemia (a surrogate marker of
dissemination).  
In conclusion, there is a limited role for ultrasound in the
diagnosis of TB. However, at a time of crisis in academic and
rural medicine in South Africa, calls for use of existing
investigations in new ways should be qualified by careful cost-
benefit analysis. We should also point out that our study was
performed in an HIV-positive population at very high risk of
TB.4 Experience elsewhere may differ, possibly resulting in
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To the Editor: In 1908 Leishman and Donovan 1 described the
protozoan Lesishmania donovani in splenic tissue. Almost a
century later leishmaniasis has emerged in new regions and
new settings.1 Recent interest in the disease has been prompted
by recognition of cases in returning US Gulf War veterans and
people with HIV infection.2 We describe a case of visceral
leishmaniasis diagnosed on bone marrow aspirate in a patient
presenting to a tertiary hospital in KwaZulu-Natal.
A 42-year-old Mozambican national, who works as a marine
merchant, was referred from a local hospital with fever,
hepatosplenomegaly and pancytopenia. He had a 6-month
history of gradual weight loss of approximately 10 kg with
intermittent fever and rigors. He was treated for hepatic
tuberculosis in a Mozambican hospital. A liver biopsy was not
done before commencement of antituberculosis therapy and
the patient did not improve after completion of this treatment.
He had been treated for malaria several years previously
while living in Mozambique. He travelled to Brazil, Argentina,
Italy and Portugal between 1995 and 1998.
On examination, the patient was febrile (39.8°C). He was
pale and had no lymphadenopathy. He had a hepatomegaly
that extended 10 cm below the costal margin and a 3 cm
splenomegaly.
The full blood count showed haemoglobin 8 g/dl
(normochromic, normocytic anaemia), platelets 132 · 109/l and
white blood cell count 1.8 · 109/l. Liver function tests revealed
a hyperglobulinaemia. He had an erythrocyte sedimentation
rate (ESR) of 113 mm/h, and his urea and electrolytes were
normal. HIV and hepatitis screens were negative. The chest
radiograph was normal. Ultrasound of the abdomen detected
no additional abnormalities. A bone marrow aspirate and
trephine were done in the first instance to investigate the
pancytopenia. A liver biopsy was scheduled, but this was
deferred when the results of the bone marrow aspirate and
trephine were received. Fig. 1 is a photomicrograph of the
marrow aspirate showing the characteristic intracellular
amastigotes of leishmaniasis.This was confirmed on the
trephine biopsy.
The patient was treated with intravenous amphotericin B 
(60 mg/kg/day) for 20 days. Renal impairment and
thrombophlebitis complicated his therapy. The renal function
improved when amphotericin B was stopped. At 3 months
after treatment the hepatosplenomegaly had resolved and a
repeat bone marrow aspirate was normal.
Discussion
This case highlights the importance of considering exotic
diseases associated with common clinical presentations, given
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Fig. 1. Bone marrow aspirate — Gram stain showing intracellular ‘dot-like’
microorganisms (magnification 1 000). Courtesy of Dr P Sturm.
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the movement of people within sub-Saharan Africa. The
diagnosis was not suspected clinically but established by a
stepwise approach to investigation. Secondly, this case
highlights the pitfalls of the all too frequent use of empirical
antituberculosis therapy without establishing a microbiological
diagnosis or setting goals for the empirical therapeutic trial.
Leishmaniasis is endemic in areas of the tropics, subtropics
and southern Europe, in settings ranging from rain forests in
the Americas to deserts in Western Asia and from rural to peri-
urban areas.1 A total of 200 million people are at risk and an
estimated 500 000 new cases occur worldwide each year.1
The protozoan is an obligate intracellular organism of the
genus Leishmania (order Kinetoplastida). Leishmania is a vector-
borne parasite transmitted by the bite of a female
phelobotomine sandfly. Parenteral and congenital transmission
also occur. In most cases, humans are the incidental host of
infection, but in India and East Africa humans appear to be the
major reservoir where peripheral parasites are taken up via the
bite of sandflies.3
Several clinical syndromes are described. These include
visceral, cutaneous and mucosal leishmaniasis. Visceral
leishmaniasis is caused by infection with L. donovani or L.
infantum, which is increasing in incidence and causing major
epidemics and high mortality.1 Visceral leishmaniasis
encompasses a wide range of manifestations and can follow an
acute, subacute or chronic course. The classic kala-azar
syndrome (Hindi for black sickness or fever) is exemplified by
a life-threatening disease after an incubation period of weeks to
months. Features include fever, cachexia, hepatosplenomegaly,
pancytopenia, and hypergammaglobulinaemia with
hypoalbuminaemia, all of which were present in our patient.
The differential diagnosis includes malaria, schistosomiasis,
cirrhosis with portal hypertension, African trypanosomiasis,
miliary tuberculosis, typhoid fever, bacterial endocarditis,
histoplasmosis, lymphoma and leukaemia.
The diagnosis depends on demonstrating the intracellular
amastigote in infected tissue (spleen, lymph node, and bone
marrow) using Giemsa’s stain. Other methods of
parasitological diagnosis include culture of infected tissue or
animal inoculation, e.g. hamster. Molecular-based applications
are currently being tested in order to avoid invasive methods.
These include the detection of immunoglobulin G (IgG)
antibody to Leishmania antigen or for parasite DNA.4
While our patient was HIV-negative, it is worth noting that
visceral leishmaniasis is an emerging opportunistic infection in
HIV-infected patients.5 A major surface molecule, the
lipophosphoglycan of L. donovani, induces HIV transcription in
CD4 cells.1 Leishmania may be newly acquired via vector-borne
transmission or contaminated syringe transmission and may
reactivate after years of latency.1
There is a high mortality rate if untreated. 1 Pentavalent
antimony compounds (sodium stibigluconate, meglumine
antimonate) are the mainstay of therapy.1 These agents are
unavailable in South Africa. Lipid formulations of
amphotericin B represent a recent advance in the therapy of
visceral leishmaniasis. In India, the use of conventional
amphotericin B has been almost 100% effective. 1 Patients with
visceral leishmaniasis should be monitored for bleeding and
intercurrent infections, such as pneumonia, tuberculosis and
dysentery.1 Response to therapy can be monitored by resolution
of fever, haemoglobin level and decrease in spleen size. 1
Splenomegaly and biochemical abnormalities resolve weeks
to months later.1 Freedom from clinical relapse for at least 6
months is the best indicator of cure. 1 The absence of parasites
does not preclude relapse until 12 months after therapy.
Relapse rates are less than 5% except in HIV-infected
individuals in whom the relapse rate is as high as 60% in the
first year.6
Leishmaniasis has protean clinical manifestations and is
difficult to diagnose without tissue diagnosis. This infection
should be suspected in patients with unexplained systemic
illness who have travelled to areas of the world where
leishmaniasis is endemic.
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